期刊文献+

强直性脊柱炎的遗传流行病学研究 被引量:10

Study on genetic epidemic of ankylosing spondylitis
原文传递
导出
摘要 目的探讨强直性脊柱炎流行病学情况及遗传方式,为优生优育和该病的防治和提供理论依据。方法分别选取山东省沿海,山东中部及西部地区三个地点,对强直性脊柱炎患病情况进行调查,患病组80例患者的家庭成员一、二、三级亲属患病人数分别是17、5、3例,通过Falconer回归法和Li—Mantel.Cart法分别估计强直性脊柱炎遗传度和分离比。结果强直性脊柱炎一级亲属患病率为7.23%,遗传度为85.94%,二级亲属患病率为0.94%,遗传度为57.4%,三级亲属患病率为0.39%,遗传度为36.2%,一、二、三级亲属平均加权遗传度为68.47%±1.64%。分离比为0.0889,说明强直性脊柱炎遗传方式为多基因遗传。结论强直性脊柱炎为多基因遗传病,遗传度是68.47%±1.64%,分离比是0.0889。通过该研究可以估计AS家系子代的发病风险,从而加强保护因素,降低该病的发病率,为优生学提供依据。 Objective To investigate the epidemiological situation and the mode of inheritance of anky- losing spondylitis (AS). Methods The AS prevalence investigation was carded out from three different areas in Shandong Province to investigate the incidence of the 80 patients' family members of sick group and calculate the heritability of AS. Results After the investigation and calculation we found the incidence of primary rela- fives was 7.23% ,the heritability was 85.94% ,the incidence of secondary relatives was 0. 94% and the herita- bility was 57.4%, the incidence of thirdly relatives was 0. 39%, the heritability is 36. 2%, the average heritabili- ty among primary, secondary and thirdly was 68.47% ± 1.64%. Separation ratio was 0. 088 9. Conclusion AS is a polygenic disease,its average heritability was 68.47%± 1.64% and separation ratio is 0. 088 9. By this re- search, the incidence risk of AS patients' pedigree offspring can be assessed, then strengthen protective factors to reduce the incidence of the disease to provide the basis for eugenics.
出处 《国际儿科学杂志》 2013年第4期413-415,共3页 International Journal of Pediatrics
基金 基金项目:山东省教育厅资助经费项目(10LF22)
关键词 强直性脊柱炎 流行病学 多基因遗传病 遗传度 Ankylosing spondylitis Epidemiology Polygenic disease Heritability
作者简介 通信作者:刘长云,Email:changyunl@163.com
  • 相关文献

参考文献7

  • 1李俊杰(综述),季加芬(综述),刘长云(审校).强直性脊柱炎的分子遗传学研究进展[J].国际儿科学杂志,2012,39(6):588-590. 被引量:2
  • 2Vander Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum, 1984,27 (4) :361-368.
  • 3Gu MM, Yuan WT, Yang JQ, et al. A genome wide scans for the sus- ceptibility gene loci to ankylosing spondylitis in Chinese population. Yi Chuan Xne Bao,2004,31 (3) :217-220.
  • 4章婕,吴振云,方格,李娟,韩布新,陈祉妍.流调中心抑郁量表全国城市常模的建立[J].中国心理卫生杂志,2010,24(2):139-143. 被引量:507
  • 5Elandt-Johson RC. Probail models and statistical methods in genetics. New York: Wiley, 1971:481-483.
  • 6Falconer DS. The inheritance of liability to certain disease estimated from the incidence among relatives. Ann Hum gent, 1965,29 ( 1 ) :51- 57.
  • 7吴报鑫,张华送,胡诞宁.多基因遗传病遗传度的计算计算法研究及疑难家系发病机率的实时咨询.上海交通大学学报,1984,6(18):115-121.

二级参考文献34

  • 1阳德华,王耘,董奇.初中生的抑郁与焦虑:结构与发展特点[J].心理发展与教育,2000,16(3):12-17. 被引量:46
  • 2刘宏军,孟琛,汤哲.北京市老年人抑郁症状的调查[J].中国心理卫生杂志,2004,18(11):794-795. 被引量:111
  • 3石岩,郭显德,刘崇庚.CES-D量表对运动员抑郁症状的测查[J].中国心理卫生杂志,1994,8(2):56-57. 被引量:9
  • 4刘贤臣,唐茂芹,陈琨,胡蕾,王爱祯.SDS和CES-D对大学生抑郁症状评定结果的比较[J].中国心理卫生杂志,1995,9(1):19-20. 被引量:95
  • 5Radloff LS. The CES-D scale: A self-report depression scale for research in the general population [J] . Appl Psychol Meas, 1977, 1:385-401.
  • 6世界卫生组织.ICD-10精神与行为障碍分类:研究用标准[M].刘平,于欣,汪向东,译.北京:人民卫生出版社,1995:79-82.
  • 7Radloff LS. The use of the Center for Epidemiologic Studies Depression Scale in adolescents and young adults [ J] . J Youth Adolesc, 1991, 20 (2) : 149 - 166.
  • 8Robinson JP,Shaver PR.性格与社会心理测量总览[M].杨宜音,彭泗清,译.台北:远流出版事业股份有限公司,1997:157-212.
  • 9刘平.流调中心用抑郁量表(Center for Epidemiologic Studies Depression Scale CES-D).中国心理卫生杂志,1999,:200-202.
  • 10Andresen EM, Malmgren JA, Carter WB, et al. Screening for depression in well older adults : evaluation of a short form of the CES-D ( Center for Epidemiologic Studies Depression Scale) [J]. Am J Prevent Med, 1994, 10:77 - 84.

共引文献507

同被引文献118

  • 1岳月,金明秀.金明秀教授治痹经验[J].辽宁中医药大学学报,2020,0(2):107-110. 被引量:5
  • 2金玉青,洪远林,李建蕊,李曦,王晓晓,吕光华.川芎的化学成分及药理作用研究进展[J].中药与临床,2013,4(3):44-48. 被引量:388
  • 3王贞佐,呼海涛,孟庆繁,王祖勇,陈义,滕利荣.海风藤的研究进展[J].时珍国医国药,2006,17(7):1305-1307. 被引量:26
  • 4骆艳丽,吴文源,李春波,张明园.医学结局研究用疼痛量表在腰痛患者中的信效度初步研究[J].中国心理卫生杂志,2006,20(11):713-715. 被引量:81
  • 5王莉莎,黄烽.生物制剂在炎性关节炎中的临床应用进展[J].中国新药杂志,2007,16(15):1149-1154. 被引量:8
  • 6Ren L,Li J,Luo R. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis[J].AMERICAN Journal OF THE MEDICAL SCIENCES,2013,(06):455-461.
  • 7Furst DE,Keystone EC,Fleischmann R. Updated consensus statement on biological agents for the treatment of rheumatic diseases,2009[J].ANNALS OF THE RHEUMATIC DISEASES,2010,(Suppl 1):S2-29.
  • 8van der Linden S,Valkenburg HA,Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis.A proposal for modification of the New York criteria[J].ARTHRITIS AND RHEUMATISM,1984,(04):361-368.
  • 9Garrett S,Jenkinson T,Kennedy LG. A new approach to defining disease status in ankylosing spondylitis:the Bath Ankylosing Spondylitis Disease Activity Index[J].Journal of Rheumatology,1994,(12):2286-2291.
  • 10Song IH,Hermann K,Haibel H. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER):a 48-week randomised controlled trial[J].ANNALS OF THE RHEUMATIC DISEASES,2011,(04):590-596.

引证文献10

二级引证文献102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部